What's in KLOW, by the milligram
KLOW vials are labelled 50/10/10/10: 50 mg of GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV, 80 mg in total. Because the four are dissolved together, every draw carries them in that ratio, so one number (the amount of blend) fixes all four.
The split, per mg and per mL
Each peptide's share is its label amount divided by 80. Multiplying any blend amount by that share gives the amount of that peptide.
| Peptide | In vial | Share | Per 1 mg blend | Per mL, 2 mL mix | Per mL, 3 mL mix |
|---|---|---|---|---|---|
| GHK-Cu | 50 mg | 62.5% | 625 mcg | 25 mg | 16.67 mg |
| BPC-157 | 10 mg | 12.5% | 125 mcg | 5 mg | 3.33 mg |
| TB-500 | 10 mg | 12.5% | 125 mcg | 5 mg | 3.33 mg |
| KPV | 10 mg | 12.5% | 125 mcg | 5 mg | 3.33 mg |
| Total | 80 mg | 100% | 1,000 mcg | 40 mg | 26.67 mg |
The fixed ratio cuts both ways. A draw sized around a particular amount of BPC-157, TB-500 or KPV carries five times as much GHK-Cu, and a draw sized around GHK-Cu carries one fifth of that amount of each of the others. The calculator's "One peptide" mode does that conversion from any target.
The four peptides
GHK-Cu
50 mg · 62.5%
A three-amino-acid peptide (glycyl-histidyl-lysine) bound to a copper ion. It is the largest part of the blend by weight.
A 2018 review by Pickart and Margolina summarised laboratory and animal work describing GHK's effects on collagen, elastin and glycosaminoglycan synthesis and on tissue repair in several models, alongside gene-expression data the authors used to explain those effects.1 The review covers GHK-Cu on its own, not in combination with the other three peptides.
BPC-157
10 mg · 12.5%
A synthetic 15-amino-acid peptide, described by the researchers who developed it as a stable gastric pentadecapeptide.
A 2014 review by Sikiric and colleagues at the University of Zagreb described its interaction with the nitric oxide system across a series of rodent injury models.2 That work is preclinical; the review does not report human trials.
TB-500
10 mg · 12.5%
A synthetic peptide associated with thymosin beta-4, a 43-amino-acid protein involved in cell migration. Sellers describe TB-500 either as full-length thymosin beta-4 or as a short fragment of it, and labels vary.
In a 1999 study in a rat full-thickness wound model, thymosin beta-4 given topically or by intraperitoneal injection increased re-epithelialisation by 42% over saline controls at day 4 and by up to 61% at day 7, with more collagen deposition and new blood vessel growth in treated wounds.3 That study used thymosin beta-4 itself, not a product sold as TB-500.
KPV
10 mg · 12.5%
A three-amino-acid peptide (lysine-proline-valine), the C-terminal end of the hormone alpha-melanocyte-stimulating hormone.
A 2008 study by Dalmasso and colleagues reported that nanomolar KPV reduced NF-kappaB and MAP kinase inflammatory signalling in human intestinal and immune cell lines, that its uptake ran through the PepT1 transporter, and that KPV in drinking water reduced inflammation in two mouse colitis models.4
The studies above examined each peptide on its own. This site has not found a published clinical trial of the four-peptide combination, and none of the four is approved by the FDA for human use. A longer look at the research on each component and on the blend is in this KLOW research review.
References
- 1.Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID 29986520
- 2.Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135. PMID 23755725
- 3.Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID 10469335
- 4.Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177